TrialClinical lung cancer2021

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Saiama N Waqar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.